Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Axogen
(NASDAQ:AXGN)
Intraday
$6.64
0.12
[1.84%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$6.64
0.12
[1.84%]
Last update: 11:48AM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 6 days from now on Thu May 2nd, before the market open
Conference call scheduled in 6 days at 8:00 AM
Click to view the webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Axogen Stock (NASDAQ:AXGN)
Axogen Stock (NASDAQ: AXGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, March 05, 2024
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Mar 5, 2024, 1:11PM
Axogen shares are trading lower. The company reported Q4 financial results.
Benzinga Newsdesk
-
Mar 5, 2024, 12:23PM
Axogen Expects 2024 Revenue Of $177M-$181M, Up 11%-14%, Versus Consensus Of $179.22M, With Gross Margin Of 76%-79%
Benzinga Newsdesk
-
Mar 5, 2024, 7:12AM
Axogen Q4 EPS $(0.06) Beats $(0.10) Estimate, Sales $42.90M Beat $41.65M Estimate
Benzinga Newsdesk
-
Mar 5, 2024, 7:09AM
Earnings Scheduled For March 5, 2024
Benzinga Insights
-
Mar 5, 2024, 5:00AM
Monday, March 04, 2024
Axogen Earnings Preview
Benzinga Insights
-
Mar 4, 2024, 10:01AM
Friday, January 19, 2024
Cantor Fitzgerald Reiterates Overweight on Axogen, Maintains $12 Price Target
Benzinga Newsdesk
-
Jan 19, 2024, 9:24AM
Thursday, January 18, 2024
Axogen Reports Topline Results From REPOSE Clinical Trial Of Axoguard Nerve Cap; Post-Marketing Study Met Its Primary Endpoint For Reduction In Pain As Measured By Visual Analog Scale
Benzinga Newsdesk
-
Jan 18, 2024, 5:01PM
Friday, January 05, 2024
Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales
Avi Kapoor
-
Jan 5, 2024, 2:30PM
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Jan 5, 2024, 1:13PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Jan 5, 2024, 12:31PM
Greenbrier Posts Upbeat Earnings, Joins Kura Sushi USA, AxoGen And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Jan 5, 2024, 10:18AM
Thursday, January 04, 2024
Axogen Reports Preliminary Q4 Revenue Of $42.7M, Up 18% Y/Y (Consensus $40.68M); Now Expects 2023 Revenue To Be At High End Of The $154M-$159M Guidance Range (Consensus $156.75M)
Benzinga Newsdesk
-
Jan 4, 2024, 4:49PM
Axogen President And CEO Karen Zaderej Plans To Retire From Company By January 2025
Benzinga Newsdesk
-
Jan 4, 2024, 4:41PM
Thursday, December 07, 2023
Canaccord Genuity Reiterates Buy on Axogen, Maintains $11 Price Target
Benzinga Newsdesk
-
Dec 7, 2023, 10:44AM
Tuesday, November 07, 2023
Axogen shares are trading higher after the company reported mixed Q3 financial results.
Benzinga Newsdesk
-
Nov 7, 2023, 2:39PM
Axogen Q3 2023 EPS $(0.10) Misses $(0.06) Estimate, Revenue $41.3M Beats $40.456M Estimate
Benzinga Newsdesk
-
Nov 7, 2023, 7:03AM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Monday, October 16, 2023
Leerink Partners Initiates Coverage On Axogen with Outperform Rating, Announces Price Target of $9
Benzinga Newsdesk
-
Oct 16, 2023, 11:37AM
Tuesday, September 26, 2023
Cantor Fitzgerald Reiterates Overweight on Axogen, Maintains $16 Price Target
Benzinga Newsdesk
-
Sep 26, 2023, 11:42AM
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 21, 2023, 12:08PM
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 15, 2023, 11:52AM
Tuesday, August 22, 2023
Cantor Fitzgerald Reiterates Overweight on Axogen, Maintains $16 Price Target
Benzinga Newsdesk
-
Aug 22, 2023, 10:45AM
Monday, August 21, 2023
Axogen Begins Processing Avance Nerve Graft At New Facility In Dayton, Ohio
Benzinga Newsdesk
-
Aug 21, 2023, 7:20AM
Tuesday, August 08, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 8, 2023, 1:32PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Aug 8, 2023, 1:31PM
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Aug 8, 2023, 1:13PM
Axogen shares are trading lower after the company reported worse-than-expected Q2 revenue results and maintained FY23 revenue guidance.
Benzinga Newsdesk
-
Aug 8, 2023, 11:49AM
Monday, August 07, 2023
Axogen Maintains FY23 Revenue Guidance $154M-$159M
Benzinga Newsdesk
-
Aug 7, 2023, 5:01PM
Axogen Q2 Adj EPS $(0.03) Beats $(0.15) Estimate, Sales $38.16M Miss $39.40M Estimate
Benzinga Newsdesk
-
Aug 7, 2023, 4:02PM
Earnings Scheduled For August 7, 2023
Benzinga Insights
-
Aug 7, 2023, 4:12AM
Wednesday, May 10, 2023
JMP Securities Reiterates Market Outperform on Axogen, Maintains $20 Price Target
Benzinga Newsdesk
-
May 10, 2023, 8:35AM
Tuesday, May 09, 2023
Axogen Reaffirms FY23 Sales Guidance Of $154M-$159M Vs. Consensus Of $156.44M
Benzinga Newsdesk
-
May 9, 2023, 7:17AM
Axogen Q1 Adjusted EPS $(0.10) Beats $(0.14) Estimate, Sales $36.66M Beat $35.37M Estimate
Benzinga Newsdesk
-
May 9, 2023, 7:16AM
Earnings Scheduled For May 9, 2023
Benzinga Insights
-
May 9, 2023, 6:03AM
Tuesday, March 28, 2023
Canaccord Genuity Reiterates Buy on Axogen, Maintains $15 Price Target
Benzinga Newsdesk
-
Mar 28, 2023, 7:42AM
Wednesday, March 15, 2023
Axogen Earnings Perspective: Return On Capital Employed
Benzinga Insights
-
Mar 15, 2023, 10:48AM
JMP Securities Reiterates Market Outperform on Axogen, Maintains $20 Price Target
Benzinga Newsdesk
-
Mar 15, 2023, 8:03AM
Tuesday, March 14, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Mar 14, 2023, 9:06AM
Axogen Q4 Adj EPS $(0.03) Beats $(0.11) Estimate, Sales $36.20M Inline
Benzinga Newsdesk
-
Mar 14, 2023, 7:03AM
Earnings Scheduled For March 14, 2023
Benzinga Insights
-
Mar 14, 2023, 4:24AM
Monday, March 13, 2023
A Preview Of Axogen's Earnings
Benzinga Insights
-
Mar 13, 2023, 10:01AM
Monday, January 09, 2023
Axogen Prelim. Q4 Revenue $36.1M vs $36.52M Est.
Bill Haddad
-
Jan 9, 2023, 7:13AM
Friday, November 11, 2022
Jefferies Assumes Axogen at Buy, Announces Price Target of $15
Benzinga Newsdesk
-
Nov 11, 2022, 9:19AM
Tuesday, November 08, 2022
Axogen shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
Benzinga Newsdesk
-
Nov 8, 2022, 1:01PM
Axogen Q3 Adj EPS $(0.01) Beats $(0.12) Estimate, Sales $36.96M Beat $36.19M Estimate
Benzinga Newsdesk
-
Nov 8, 2022, 7:01AM
Earnings Scheduled For November 8, 2022
Benzinga Insights
-
Nov 8, 2022, 4:32AM
Monday, September 12, 2022
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Lisa Levin
-
Sep 12, 2022, 3:23AM
Wednesday, August 03, 2022
Axogen: Q2 Earnings Insights
Benzinga Insights
-
Aug 3, 2022, 4:55PM
Axogen Q2 EPS $(0.06) Beats $(0.15) Estimate, Sales $34.50M Beat $33.85M Estimate
Benzinga Newsdesk
-
Aug 3, 2022, 4:15PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch